BioAtla, Inc.

As of June 30, 2026, BioAtla, Inc. carries a market capitalization of 6.89M, placing it among publicly traded companies globally. Its enterprise value stands at 11.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioAtla, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, BioAtla, Inc. has 1.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.67, and the price-to-book ratio stands at -0.19.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.20M versus a market cap of 6.89M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioAtla, Inc. maintains a current ratio of 0.20, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -171.72, reflecting losses generated across the asset base. The company generates approximately 170,854.27 in revenue per employee across its workforce of 49.75, a quick read on workforce productivity versus industry peers.

As of the close on August 28, 2026, BioAtla, Inc.'s stock has declined approximately 91.74% over the past 52 weeks. The 50-day moving average sits at 3.54, while the 200-day moving average is 12.94.

Over the twelve months ended June 30, 2026, BioAtla, Inc. generated 8.50M in revenue and converted that into -31.45M in net income, yielding earnings per share of -22.73. EBITDA reached -31.93M, while operating income came in at -32.12M.

As of June 30, 2026, BioAtla, Inc. holds 1.54M in cash and equivalents against 5.86M in total debt, resulting in a net debt position of -1.54M. Total book value stands at -36.24M, with working capital of -16.76M providing operational flexibility.

BioAtla, Inc. produced -23.48M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -377.94 and net profit margin of -370.05 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -409.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -99.03, meaning BioAtla, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioAtla, Inc.'s most recent stock split took place on April 6, 2026 with a 50:1 split ratio.

As of June 30, 2026, BioAtla, Inc. has an Altman Z-Score of -93.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.